Legal & General Group Plc Purchases New Position in Sarepta Therapeutics, Inc. $SRPT

Legal & General Group Plc purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 877,627 shares of the biotechnology company’s stock, valued at approximately $15,771,000.

Several other hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 636 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Sarepta Therapeutics by 3.3% during the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 851 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in Sarepta Therapeutics by 3.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 875 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

SRPT opened at $20.86 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $25.32. The firm has a market cap of $2.20 billion, a P/E ratio of -7.19, a price-to-earnings-growth ratio of 0.31 and a beta of 0.24. The business’s fifty day moving average is $17.73 and its 200-day moving average is $18.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. During the same quarter in the previous year, the firm earned $2.02 earnings per share. Sarepta Therapeutics’s revenue for the quarter was down 34.3% compared to the same quarter last year. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of research reports. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, July 9th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.06.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.